7.41

3.06% 0.22

Pre-market: 7.25 -0.16 -2.16%

Achieve Life Sciences Inc (ACHV)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Achieve Life Sciences Inc stock is traded at $7.41, with a volume of 987.30K. It is up +3.06% in the last 24 hours and up +4.96% over the past month. Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.

Previous Close:

$7.19

Open:

$7.2

24h Volume:

987.30K

Relative Volume:

0.72

Market Cap:

$763.99M

Revenue:

$17.82M

Net Income/Loss:

$-51.99M

P/E Ratio:

-6.6428

EPS:

-1.1155

Net Cash Flow:

$-45.31M

1W Performance:

+5.71%

1M Performance:

+4.96%

6M Performance:

+112.32%

1Y Performance:

+140.58%

1-Day Range:

$0.00

1-Week Range:

$6.8901

$7.48

52-Week Range:

$2.62

$8.64

Achieve Life Sciences Inc Stock (ACHV) Company Profile

Name

Achieve Life Sciences Inc

Sector

Healthcare (1050)

Industry

Biotechnology (591)

Phone

425-686-1500

Address

22722 29TH DR. SE, SEATTLE, BC

Employee

Twitter

Next Earnings Date

2026-11-05

Latest SEC Filings

ACHV's Discussions on Twitter

Compare ACHV vs VRTX, MRNA, REGN, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACHV Achieve Life Sciences Inc	7.41	763.99M	17.82M	-51.99M	-45.31M	-1.1155
VRTX Vertex Pharmaceuticals Inc	510.08	129.29B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	225.00	89.83B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	746.54	76.86B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	825.03	51.88B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.76	40.67B	742.00K	-1.37B	-1.07B	-7.0731

Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-30-26	Initiated	Stifel	Buy
Aug-13-26	Initiated	Morgan Stanley	Overweight
Jun-26-26	Resumed	Raymond James	Strong Buy
Apr-21-26	Initiated	Canaccord Genuity	Buy
Nov-25-25	Initiated	Citizens JMP	Mkt Outperform
Aug-21-25	Initiated	H.C. Wainwright	Buy
Nov-14-24	Initiated	Rodman & Renshaw	Buy
Sep-27-24	Initiated	Raymond James	Strong Buy
May-10-23	Reiterated	Maxim Group	Buy
Jun-23-21	Initiated	Oppenheimer	Outperform

View All

Achieve Life Sciences Inc Stock (ACHV) Latest News

Oct 06, 2026

Achieve Life Sciences CFO Benjamin Halladay Files Initial SEC Ownership Disclosure - Kalkine Media

Oct 06, 2026

CFO receives a 200,000-share stock grant plus options at Achieve Life Sciences (ACHV). - Stock Titan

Oct 06, 2026

[Form 3] ACHIEVE LIFE SCIENCES, INC. Initial Statement of Beneficial Ownership - Stock Titan

Oct 06, 2026

Achieve Life Sciences Announces Granting of New Hire Inducement Awards - Yahoo Finance

Oct 06, 2026

Oct 04, 2026

Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates - Lelezard

Oct 04, 2026

Oct 02, 2026